Rezurock™
Drug - Rezurock™ (belumosudil) [Kadmon Pharmaceuticals, LLC.]
April 2022
Therapeutic area - Immunosuppressives, Oral
Initial approval criteria
- Patient is at least 12 years old AND
- Patient has a diagnosis of chronic graft-versus-host disease (chronic GVHD) AND
- Patient has failed at least two prior lines of systemic therapy AND
- Rezurock is prescribed by or in consultation with a transplant specialist AND
- Comprehensive review of the patient’s medication profile is conducted; and if applicable, interacting drugs are identified and dosage is adjusted accordingly AND
- Patient of reproductive potential is advised of the potential risk to a fetus and to use effective contraception
Renewal criteria
- Patient continues to meet initial approval criteria AND
- Patient has not experienced disease progression AND
- Patient has not experienced unacceptable adverse drug effects (e.g., severe nausea, severe vomiting, severe diarrhea, hepatotoxicity)
Quantity limits
Background information
Rezurock is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Questions
MHCP Provider Resource Center 651-431-2700 or 800-366-5411
